Research prototype, not medical advice.

In the PEARL trial (114 people, 5-10 mg/week for 48 weeks), rapamycin was well tolerated with a modest signal in women at 10 mg (lean mass, pain); the compounded form was poorly absorbed.

Confidence
Debated
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Deregulated nutrient sensingRapamycin (and analogues: everolimus)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
Moel et al. · Aging 2025
— Verified